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CASE REPORTInhaled Loxapine for Agitation in Intoxicated
Patients: A Case SeriesCarlos Roncero, MD, PhD,*†‡}|| Elena Ros-Cucurull, MD,*†‡ Raúl Felipe Palma-Álvarez, MD,*‡
Alfonso Carlos Abad, MD,*‡ Christian Fadeuilhe, MD,‡
Miquel Casas, MD, PhD,†‡ and Lara Grau-López, MD, PhD*†‡Objectives: Episodes of agitation are frequent in intoxicated patients who
have a substance use disorder, a psychiatric disorder or both (dual diagnosis).
For managing the agitation, it is necessary to act promptly in a safe environ-
ment and addressing any underlying etiology. Inhaled loxapine improves
symptoms of agitation in adults with psychiatric disorders (eg, schizophrenia)
within 10minutes of administration. Recently, some reports have documented
the usefulness of loxapine in dual diagnoses patients with agitation. However,
the efficacy of loxapine in intoxicated patients has not been deeply addressed.
Methods: This report describes a case series of 12 patients (with addic-
tion or dual disorder) who received inhaled loxapine for symptoms of psy-
chomotor agitation during intoxication with different substances (eg,
alcohol, cannabis, or cocaine) at 1 center in Spain.
Results: Data from 12 patients were reviewed, 5 patients were attended at
the emergency room, 4 at the addiction and dual diagnosis unit, and 3 were
treated during hospitalization for detoxification. All patients were under ef-
fects of substances. They had substance use disorder (including cannabis,
cocaine, alcohol, hypnotics, and hallucinogens), and almost all (90%) pre-
sented 1 or more psychiatric disorders. One dose of inhaled loxapine was
effective in 9 patients (75%), and in 3 patients, a second dose was required.
Only mild dizziness was reported in 1 patient after the second dose.
Conclusions: The acute agitation was effectively and quickly managed
with inhaled loxapine in all intoxicated patients and enabled the appropriate
clinical evaluation of the agitated state and the patient's management.
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S ubstance use disorders (SUDs) and psychiatric disorders (oreven both diagnoses, namely dual diagnosis) are a frequent
factor for agitation episodes in intoxicated patients.1–5 Substance
intoxication is one of the main etiologies of psychomotor agitation
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Clinical Neuropharmacology • Volume 40, Number 6, November/Decea state of psychomotor agitation are common users of emergency
departments. Their management includes providing a safe envi-
ronment, managing agitation to enable appropriate clinical evalu-
ation of the agitated state, and addressing the underlying etiology.
To allow a safe management of the agitated patient is neces-
sary a “quick intervention,” including nonpharmacological and
pharmacological strategies.8 Pharmacological treatment consists
in achieving patient's tranquilization and includes mainly benzo-
diazepines or antipsychotics, which are chosen depending on
the absence or presence of psychotic symptoms.3 Low doses of
neuroleptics are recommended for intoxications in agitated pa-
tients with history of alcohol and sedative use, whereas benzo-
diazepines are preferred if there is a suspicion of substance
intoxication other than alcohol (eg, with amphetamines, cocaine,
or phencyclidine).3 Nevertheless, antipsychotics are preferred
over benzodiazepines for patients with a known psychiatric disor-
der (schizophrenia, schizoaffective disorder, bipolar disorder), be-
cause they address the underlying disease.3,5
There are few data on the use of antipsychotics, other than
haloperidol, for agitation secondary to intoxication in patients
with underlying psychiatric pathology.3,5,9 New intramuscular for-
mulations for antipsychotics provide faster effect, but they are in-
vasive and are not well received by most of the patients.10 The
most frequent complications of rapid tranquilization depend on
the pharmacologic profile but also can derive from the interactions
with other addictive substances or the existence of subjacent dis-
eases.9 Thus, complications from sedatives reside in their long du-
ration of action and the risk of lethality in overdose, especially
when they are combined with other medications or alcohol.3 On
the other hand, the use of antipsychotics may result in extrapyra-
midal adverse effects, QTc prolongation, arrhythmias, potential
serotonin syndrome, and neuroleptic malignant syndrome.11 Fur-
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(including patients undergoing alcohol or sedative-hypnotic with-
drawal)12 and not to mention that antipsychotics are related to
metabolic syndrome.13 Hence, there is a need for treatments with
a good safety profile and low drug interactions, with fast onset but
enough duration of action, easy to administer, and nontraumatic.7
As a new alternative, inhaled loxapine has demonstrated to
reduce mild to moderate agitation in 10 minutes in patients with
schizophrenia or bipolar disorder.14–16 Response rates observed
with inhaled loxapine were similar to those observed with the in-
tramuscular administration of other antipsychotics.17 Inhaled
loxapine may have a role in the treatment of substance-induced
agitation, but data on the use of inhaled loxapine in intoxicated
patients are lacking.18 Recently, a case series of 14 agitated pa-
tients with dual diagnosis has been described; 4 patients pre-
sented an intoxication state and were treated with inhaled
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8 46/M Alcohol Alcohol, nicotine Not perform
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remission (>2 y)
Not perform
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282 www.clinicalneuropharm.comwas rapid, effective, and well accepted in all patients presenting
with acute agitation and facilitated the cooperation of the patient
and an adequate management of the disease.19 Although, it is im-
portant to point out that inhaled loxapine was used as off-label in
that report, as has been used in other diagnoses such as border-
line personality disorder.20
The current report aims to extend the experience with in-
haled loxapine to 12 intoxicated patients attending the emergency
service and the addiction and dual diagnosis unit at 1 center
in Spain. All patients had a SUD, and almost all patients had an
underlying psychiatric disorder. Inhaled loxapine was used to
treat agitation.
CASES
Cases include 12 patients in an intoxicated state and were
treated with inhaled loxapine; those patients were attended at
the emergency room (ER) (n = 5), at the addiction and dualicological
ing Other Diagnoses Previous Hospitalizations
ed Bipolar I and anxiety
disorders
Several hospitalizations
because of poor treatment
adherence and decompensation
THC Paranoid schizophrenia Several hospitalizations
ed Paranoid schizophrenia None







cocaine Bipolar disorder I,
obsessive/ compulsive
disorder at childhood
One hospitalization for delirium







ed Cyclothymic disorder None







ed ADHD and induced
psychosis
None
intramuscular; M, male; NR, not reported; THC, tetrahydrocannabinol.
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(n = 3) at the Hospital of Vall de Hebron in Barcelona, Spain, from
December 2014 to April 2016.
All patients presented a SUD, namely nicotine (n = 9;
75.0%), alcohol (n = 7; 58.3%), cannabis (n = 6; 50.0%), cocaine
(n = 6; 50.0%), and others (amphetamines [n = 2; 16.7%], hyp-
notics [n = 1; 8.3%], and hallucinogens [n = 1; 8.3%]). Almost
all (9/10; 90%) presented 1 or more psychiatric disorders accord-
ing toDiagnostic and Statistical Manual of Mental Disorders, 5th
Edition, including personality disorder (n = 4; 33.3%), bipolar I
disorder (n = 3; 25%), schizophrenia (n = 2; 16.7%), psychotic
disorder (n = 1; 8.3%), cyclothymic disorder (n = 1; 8.3%), or anx-
iety disorder (n = 2; 16.7%). Patients presented at the center in a
state of substance intoxication due to alcohol (n = 7; 58.3%), can-
nabis (n = 6; 50.0%), cocaine (n = 4; 33.3%), or ayahuasca (n = 1;
8.3%), which was confirmed by urine toxicological testing in
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© 2017 The Author(s). Published Wolters Kluwer Health, Inc.in 9 patients (75%) within 5 to 15 minutes after administration
(<5 minutes in 8 patients; 66.7%). In 3 patients (no. 1, no. 3,
and no. 6), a second dosewas required between 2 and 4 hours after
the first one. Clonazepam treatment was started concomitantly
with loxapine for the agitation episode, because of the appearance
of abstinence or anxiety, in 2 patients (no. 7 and no. 12). A third
patient (no. 4) required physical restraint and rescue medication
(intramuscular haloperidol and levomepromazine). No other res-
cue medication was needed during the acute episodes of agitation.
Only mild dizziness was reported in 1 patient after the second
dose. A daily dose of loxapine was effective for the treatment of
daily agitation episodes during the first 5 days of hospitalization
in 1 patient (no. 2).
Vital signs and other parameters were monitored during
the medical intervention according to the hospital protocol for
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To date, there are scarce clinical data on the use of inhaled
loxapine in intoxicated patients because usually intoxication or
having a positive drug screening was exclusion criteria in clinical
trials that evaluated inhaled loxapine as treatment for agitation.
The current study constitutes a report on the effectiveness and
safety of inhaled loxapine in patients presenting with agitation
during substance-related intoxication.
Inhaled loxapine was well received by the patient and re-
duced the perception of coercion or forced medication, enabling
the patient's cooperation. In most cases, only 1 dose was needed
to calm the patients, which was effective within minutes in a con-
siderable proportion of them. A 66.7% (n = 8) of patients did not
require an additional dose (n = 3, 25%) or rescue medication
(n = 1) within 24 hours. These rates are comparable with those re-
ported in the clinical trials with inhaled loxapine in patients with
schizophrenia (60.9%) or bipolar disorders (61.5%).15,16 A regi-
men with a benzodiazepine was initiated, concomitantly with in-
haled loxapine, in 2 cases. After control of acute agitation
symptoms, patients received regular treatment immediately, and
in these 2 cases, clonazepam was deemed the most appropriate
treatment for their underlying disorder. The advantages of inhaled
loxapine over the antipsychotic medication used traditionally re-
side in the route of administration, which is equivalent to the intra-
venous and faster than the intramuscular one but has better
tolerability and is more patient friendly. Inhaled loxapine was well
tolerated in these case series, and there were no reporting of
respiratory signs/symptoms.
The most prevalent substances used were alcohol, cannabis,
and cocaine use (apart from tobacco), and these were the most
consumed substances causing intoxication. There is plenty of pub-
lished literature on the abuse of cocaine,21 alcohol,22 or cannabis23
as correlated to agitation episodes in patients with SUD and dual
diagnosis and represent a major public health problem and a cause
of concern in the emergency and outpatient facilities.24
For a better management of the patient, it is important to de-
termine what specific substances the patient have been consum-
ing, and the use of urine (or blood) toxicology screening tests
is an important aid at the ER.25 However, the results of the test
screening are not always a determining factor, and the substance
might not be detectable through the routine analysis.2 In the cur-
rent study, the substance intoxication was detectable in 4 cases,
but it was not assessed in the other 8 cases because of several rea-
sons (the patient referred active consumption at admission, or the
urine sampling was not feasible). Specific clinical signs and
symptoms are also helpful, particularly psychomotor agitation is
frequent in patients with stimulant intoxication (induced by co-
caine or amphetamine) or alcohol-intoxicated patients, and in
these patients, the use of a neuroleptic is recommended.
This article should be analyzed focusing in limitations, es-
pecially because it is a small case series and the use of inhaled
loxapine as off-label in some cases. Nevertheless, the use of
somemedications as off-label in psychiatry and SUD is frequent26
and inhaled loxapine has been administered as off-label in some re-
ports, for example in borderline personality disorder20 and in dual
diagnoses patients.21 Finally, effectiveness was not evaluated with
a standard instrument but onlywith clinical assessment (considering
tranquilization and use of additional medication or doses).
Conclusively, inhaled loxapine would have a role in agitation
related to substance intoxication, especially in dual diagnosis pa-
tients, improving cooperation and outcomes at the ER. Therefore,
we may comment (and recommend) that this medication is a use-
ful tool in drug users who are agitated and intoxicated at the same
time. Although, usual contraindications of this medication have284 www.clinicalneuropharm.comalways to be taken into consideration (eg, respiratory diseases).
These case series are illustrative of the realworld at the emergency
and psychiatric services and substantiate the effectiveness and
safety of inhaled loxapine for treating agitation, enabling the ap-
propriate clinical evaluation of the agitated state and the adequate
management of the intoxicated patients attended at our hospital.
Studies with a higher sample of intoxicated patients who consume
different and multiple types of drugs are needed to better charac-
terize the potential interactions of loxapine.REFERENCES
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